DK3200815T3 - Fremgangsmåder og sammensætninger til behandling af cancer - Google Patents

Fremgangsmåder og sammensætninger til behandling af cancer Download PDF

Info

Publication number: DK3200815T3
Authority: DK; Denmark
Prior art keywords: compositions; methods; treating cancer; cancer; treating
Prior art date: 2014-10-02

Application number

DK15847792.7T

Other languages

English (en)

Inventor

Jose R Conejo-Garcia

Alfredo Perales-Puchalt

Original Assignee

Wistar Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-02

Filing date

2015-09-30

Publication date

2021-05-10

2015-09-30 Application filed by Wistar Inst filed Critical Wistar Inst

2021-05-10 Application granted granted Critical

2021-05-10 Publication of DK3200815T3 publication Critical patent/DK3200815T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Hematology (AREA)

DK15847792.7T 2014-10-02 2015-09-30 Fremgangsmåder og sammensætninger til behandling af cancer DK3200815T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462059068P	2014-10-02	2014-10-02
US201562202824P	2015-08-08	2015-08-08
PCT/US2015/053128 WO2016054153A1 (en)	2014-10-02	2015-09-30	Methods and compositions for treating cancer

Publications (1)

Publication Number	Publication Date
DK3200815T3 true DK3200815T3 (da)	2021-05-10

Family

ID=55631412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15847792.7T DK3200815T3 (da)	2014-10-02	2015-09-30	Fremgangsmåder og sammensætninger til behandling af cancer

Country Status (16)

Country	Link
US (4)	US10259855B2 (da)
EP (1)	EP3200815B1 (da)
CN (2)	CN106999552B (da)
CA (1)	CA2989807C (da)
CY (1)	CY1125797T1 (da)
DK (1)	DK3200815T3 (da)
ES (1)	ES2870607T3 (da)
HR (1)	HRP20210705T1 (da)
HU (1)	HUE054673T2 (da)
LT (1)	LT3200815T (da)
PL (1)	PL3200815T3 (da)
PT (1)	PT3200815T (da)
RS (1)	RS61929B1 (da)
SI (1)	SI3200815T1 (da)
SM (1)	SMT202100273T1 (da)
WO (1)	WO2016054153A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10538568B2 (en) *	2014-11-04	2020-01-21	The Trustees Of The University Of Pennsylvania	Methods and compositions of a follicle stimulating hormone receptor immunoreceptor
JP2019510786A (ja) *	2016-04-05	2019-04-18	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	免疫療法におけるＴＧＦβの阻害
IT201600101852A1 (it) *	2016-10-11	2018-04-11	Abresearch Srl	Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia dei tumori
IT201600101870A1 (it) *	2016-10-11	2018-04-11	Abresearch Srl	Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia del neuroblastoma
IL265889B2 (en) *	2016-10-11	2025-04-01	Oncogreen Therapeutics Sa	FSH receptor ligands for tumor diagnosis and treatment
US12485102B2 (en)	2017-08-02	2025-12-02	The Wistar Institute Of Anatomy And Biology	Methods and compositions for treating cancer
EP3676378A4 (en)	2017-08-31	2021-06-09	The New York Genome Center	PROCEDURES AND COMPOSITIONS USING CRIMP-CPF1 AND PAIRED GUIDE-CRISPR-RNA FOR PROGRAMMABLE GENOMIC DELETIONS
US11786557B2 (en)	2017-10-02	2023-10-17	Fred Hutchinson Cancer Center	Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells
WO2019136288A1 (en) *	2018-01-05	2019-07-11	Maxcyte, Inc.	Chronic car treatment for cancer
CN113613725B (zh) *	2018-11-05	2025-09-23	路德维格癌症研究所有限公司	人源化和变体TGF-β1特异性抗体及其方法和用途
US20220031747A1 (en) *	2019-01-07	2022-02-03	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Foxp1-ablated chimeric cells
CN113474458A (zh) *	2019-01-30	2021-10-01	威斯塔解剖学和生物学研究所	靶向癌症抗原的dna编码的双特异性t细胞连接子以及在癌症治疗中的使用方法
CN114450013A (zh) *	2019-04-12	2022-05-06	爱莫里大学	用于促进造血细胞的细胞毒性的组合物和方法
WO2021168421A1 (en) *	2020-02-20	2021-08-26	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Method of enhancing immunotherapy using er stress pathway inhibitors
US20240101626A1 (en) *	2021-02-12	2024-03-28	Kar Muthumani	Consensus prostate antigens, nucleic acid molecules encoding the same, and vaccines and uses comprising the same
CN115975056B (zh) *	2023-02-07	2023-12-01	徐州医科大学	利用天然蛋白tsh作为抗原结合位点构建靶向tshr的car-t细胞

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5702702A (en)	1992-03-30	1997-12-30	The Wistar Institute Of Anatomy And Biology	Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer
KR100987360B1 (ko)	2001-11-21	2010-10-12	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법
US7081446B2 (en)	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
AU2003270063A1 (en)	2002-09-04	2004-03-29	The Trustees Of The University Of Pennsylvania	Immune cell receptor ligand and immune cell receptor
EP2000160A3 (en)	2002-10-30	2009-03-11	Gambro Lundia AB	Method and apparatuses for determining the efficiency of dialysis
ES2871907T3 (es)	2004-01-23	2021-11-02	Msd Italia Srl	Portadores de vacuna de adenovirus de chimpancé
WO2006084209A2 (en)	2005-02-03	2006-08-10	Benitec, Inc.	Rnai expression constructs
GB0725201D0 (en) *	2007-12-24	2008-01-30	Asterion Ltd	Peptide fusion proteins
ES2633453T3 (es)	2008-01-24	2017-09-21	Esperance Pharmaceuticals	Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos
EP2090322A1 (en)	2008-02-18	2009-08-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of fsh receptor ligands for diagnosis and therapy of cancer
CN102369021B (zh) *	2008-12-19	2016-09-07	宏观基因有限公司	共价双抗体及其用途
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013044225A1 (en)	2011-09-22	2013-03-28	The Trustees Of The University Of Pennsylvania	A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
US9226936B2 (en)	2011-10-28	2016-01-05	The Wistar of Anatomy and Biology	Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
CN105073779A (zh) *	2012-11-15	2015-11-18	埃斯佩兰斯医药公司	促卵泡激素(fsh)/裂解结构域融合构建体与其制备和使用的方法
CN103509121B (zh) *	2012-11-22	2015-01-28	苏州康宁杰瑞生物科技有限公司	一种fsh融合蛋白及其制备方法和用途
US10538568B2 (en)	2014-11-04	2020-01-21	The Trustees Of The University Of Pennsylvania	Methods and compositions of a follicle stimulating hormone receptor immunoreceptor

2015
- 2015-09-30 EP EP15847792.7A patent/EP3200815B1/en active Active
- 2015-09-30 HU HUE15847792A patent/HUE054673T2/hu unknown
- 2015-09-30 DK DK15847792.7T patent/DK3200815T3/da active
- 2015-09-30 WO PCT/US2015/053128 patent/WO2016054153A1/en not_active Ceased
- 2015-09-30 PT PT158477927T patent/PT3200815T/pt unknown
- 2015-09-30 CA CA2989807A patent/CA2989807C/en active Active
- 2015-09-30 SM SM20210273T patent/SMT202100273T1/it unknown
- 2015-09-30 US US15/515,442 patent/US10259855B2/en active Active
- 2015-09-30 SI SI201531592T patent/SI3200815T1/sl unknown
- 2015-09-30 CN CN201580065382.9A patent/CN106999552B/zh active Active
- 2015-09-30 ES ES15847792T patent/ES2870607T3/es active Active
- 2015-09-30 LT LTEP15847792.7T patent/LT3200815T/lt unknown
- 2015-09-30 PL PL15847792T patent/PL3200815T3/pl unknown
- 2015-09-30 HR HRP20210705TT patent/HRP20210705T1/hr unknown
- 2015-09-30 CN CN202111464043.1A patent/CN114150018A/zh active Pending
- 2015-09-30 RS RS20210553A patent/RS61929B1/sr unknown
2019
- 2019-02-21 US US16/281,472 patent/US11248033B2/en active Active
2021
- 2021-05-31 CY CY20211100466T patent/CY1125797T1/el unknown
- 2021-12-27 US US17/562,643 patent/US12384826B2/en active Active
2025
- 2025-07-15 US US19/269,573 patent/US20250340609A1/en active Pending

Also Published As

Publication number	Publication date
CN114150018A (zh)	2022-03-08
US20250340609A1 (en)	2025-11-06
ES2870607T3 (es)	2021-10-27
CN106999552B (zh)	2021-12-28
PT3200815T (pt)	2021-05-07
PL3200815T3 (pl)	2021-10-18
US10259855B2 (en)	2019-04-16
CN106999552A (zh)	2017-08-01
CY1125797T1 (el)	2024-02-16
EP3200815A1 (en)	2017-08-09
RS61929B1 (sr)	2021-06-30
CA2989807A1 (en)	2016-04-07
HRP20210705T1 (hr)	2021-07-23
SI3200815T1 (sl)	2021-11-30
US11248033B2 (en)	2022-02-15
SMT202100273T1 (it)	2021-07-12
US20190248862A1 (en)	2019-08-15
HUE054673T2 (hu)	2021-09-28
WO2016054153A1 (en)	2016-04-07
CA2989807C (en)	2023-07-04
US20220185861A1 (en)	2022-06-16
EP3200815B1 (en)	2021-03-03
LT3200815T (lt)	2021-07-26
US20170226176A1 (en)	2017-08-10
EP3200815A4 (en)	2018-04-25
US12384826B2 (en)	2025-08-12

Publication	Publication Date	Title
DK3245225T3 (da)	2021-10-18	Sammensætninger og fremgangsmåder til behandling og detektering af cancere
DK3200815T3 (da)	2021-05-10	Fremgangsmåder og sammensætninger til behandling af cancer
DK3386518T3 (da)	2025-09-15	Metoder og sammensætninger til behandling af en serpinc1-associeret forstyrrelse
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
IL255261A0 (en)	2017-12-31	Methods for treating cancer
DK3288581T3 (da)	2021-01-11	Fremgangsmåde til behandling af cancer
DK3134130T3 (da)	2019-08-26	Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3125927T3 (da)	2021-04-19	Fremgangsmåder og sammensætninger til immunmodulering
DK3137605T3 (da)	2020-12-14	Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3888658T3 (da)	2024-03-18	Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
BR112017011771A2 (pt)	2018-07-10	métodos e composições para o tratamento de câncer
DK3092256T3 (da)	2022-06-20	Forbindelser og sammensætninger til immunterapi
DK3206497T3 (da)	2020-12-21	Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion
DK3206493T3 (da)	2020-08-10	Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3215147T3 (da)	2024-04-02	Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3286311T3 (da)	2021-05-17	Fremgangsmåde til behandling af maligniteter
DK2994533T3 (da)	2019-07-01	Fremgangsmåder og sammensætninger til behandling af cancer
DK3108009T3 (da)	2021-06-07	Fremgangsmåder og sammensætninger til DNA-profilering
DK3201351T3 (da)	2021-02-22	Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3377516T3 (da)	2022-09-19	Sammensætning til behandling af cancer
IL252182A0 (en)	2017-07-31	Method for treating cancer
DK3144001T3 (da)	2021-11-15	Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK2941258T3 (da)	2019-12-16	Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier
DK3204386T3 (da)	2021-05-25	Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3102232T3 (da)	2020-04-20	Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst